Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 1,081 - 1,100 results of 46,288 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((step decrease) OR (mean decrease)) ))', query time: 0.71s Refine Results
  1. 1081
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1082
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1083
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1084
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1085
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1086
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1087
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1088
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1089
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1090
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1091
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1092
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1093
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1094
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1095
    Flow chart of the expression-based functional screen, with validation steps.

    Flow chart of the expression-based functional screen, with validation steps. by Mohamad Karaky (8910497)

    Published 2022
    Save to List
    Saved in:
  16. 1096
    Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018.

    Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018. by Getachew Ossabo Babore (10788843)

    Published 2021
    Save to List
    Saved in:
  17. 1097
    Inflammatory conditions decrease CD36 expression and CD36-mediated <i>Pf</i>PEs phagocytosis through downregulation of PPARγ.

    Inflammatory conditions decrease CD36 expression and CD36-mediated <i>Pf</i>PEs phagocytosis through downregulation of PPARγ. by David Olagnier (205583)

    Published 2011
    Save to List
    Saved in:
  18. 1098
    Mean and standard deviation values for the Impulse during the first 50 ms of stance (Imp50) during running shod (SH) and barefoot (BF), in both PRE and POST training, where (<sup>a</sup>) means difference between PRE and POST in SH running; and (<sup>b</sup>) means difference between PRE and POST in BF running.

    Mean and standard deviation values for the Impulse during the first 50 ms of stance (Imp50) during running shod (SH) and barefoot (BF), in both PRE and POST training, where (<sup>a... by Ana Paula da Silva Azevedo (3373688)

    Published 2016
    Save to List
    Saved in:
  19. 1099
    Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line.

    Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line. by Benedikt B. Kaufer (341018)

    Published 2013
    Save to List
    Saved in:
  20. 1100
    Box plot JRS, EQ-5D-5L, and NEI-VFQ-25 at each visit.

    Box plot JRS, EQ-5D-5L, and NEI-VFQ-25 at each visit. by Parima Hirunwiwatkul (14797370)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: